|
Name |
Calvasterol B
|
| Molecular Formula | C28H40O4 | |
| IUPAC Name* |
(9S,10S,13R,14S,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-9,14-dihydroxy-10,13-dimethyl-2,11,12,15,16,17-hexahydro-1H-cyclopenta[a]phenanthrene-3,6-dione
|
|
| SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]3(C2=CC(=O)C4=CC(=O)CC[C@@]43C)O)C)O
|
|
| InChI |
InChI=1S/C28H40O4/c1-17(2)18(3)7-8-19(4)21-10-12-27(31)24-16-23(30)22-15-20(29)9-11-25(22,5)28(24,32)14-13-26(21,27)6/h7-8,15-19,21,31-32H,9-14H2,1-6H3/b8-7+/t18-,19+,21+,25-,26+,27+,28+/m0/s1
|
|
| InChIKey |
PPPHAARYIMWGSU-VWLVVCIOSA-N
|
|
| Synonyms |
Calvasterol B; (22e,24r)-9a,14a-dihydroxyergosta-4,7,22-trien-3,6-dione; 162857-86-5
|
|
| CAS | NA | |
| PubChem CID | 11743978 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 440.6 | ALogp: | 3.6 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 74.6 | Aromatic Rings: | 4 |
| Heavy Atoms: | 32 | QED Weighted: | 0.581 |
| Caco-2 Permeability: | -4.775 | MDCK Permeability: | 0.00002050 |
| Pgp-inhibitor: | 0.951 | Pgp-substrate: | 0.009 |
| Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.039 |
| 30% Bioavailability (F30%): | 0.01 |
| Blood-Brain-Barrier Penetration (BBB): | 0.503 | Plasma Protein Binding (PPB): | 88.41% |
| Volume Distribution (VD): | 1.029 | Fu: | 2.58% |
| CYP1A2-inhibitor: | 0.037 | CYP1A2-substrate: | 0.967 |
| CYP2C19-inhibitor: | 0.314 | CYP2C19-substrate: | 0.833 |
| CYP2C9-inhibitor: | 0.283 | CYP2C9-substrate: | 0.025 |
| CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.02 |
| CYP3A4-inhibitor: | 0.701 | CYP3A4-substrate: | 0.958 |
| Clearance (CL): | 2.329 | Half-life (T1/2): | 0.102 |
| hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.666 |
| Drug-inuced Liver Injury (DILI): | 0.056 | AMES Toxicity: | 0.021 |
| Rat Oral Acute Toxicity: | 0.654 | Maximum Recommended Daily Dose: | 0.953 |
| Skin Sensitization: | 0.607 | Carcinogencity: | 0.889 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.015 |
| Respiratory Toxicity: | 0.983 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002985 | ![]() |
1.000 | D0G5CF | ![]() |
0.333 | ||
| ENC004905 | ![]() |
0.700 | D0G8OC | ![]() |
0.328 | ||
| ENC001990 | ![]() |
0.650 | D06JPB | ![]() |
0.328 | ||
| ENC002984 | ![]() |
0.570 | D04GJN | ![]() |
0.328 | ||
| ENC002480 | ![]() |
0.532 | D0L2LS | ![]() |
0.302 | ||
| ENC004615 | ![]() |
0.527 | D0I2SD | ![]() |
0.283 | ||
| ENC003120 | ![]() |
0.487 | D0R7JT | ![]() |
0.282 | ||
| ENC004906 | ![]() |
0.487 | D0Z1XD | ![]() |
0.278 | ||
| ENC006035 | ![]() |
0.483 | D0IX6I | ![]() |
0.276 | ||
| ENC004864 | ![]() |
0.483 | D0G8BV | ![]() |
0.271 | ||